Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05741333 · ClinicalTrials.gov registry record · NA
In-Office Clinical Study of the Solo+ TTD
A NA study of Otitis Media and Ear Infection, sponsored by AventaMed DAC.
- Recruiting
- Registry status
- NA
- Development phase
- 66
- Enrollment target
- 7
- Study locations
NCT05741333: Recruiting NA study of Otitis Media and Ear Infection, sponsored by AventaMed DAC.
NCT05741333 is a NA study of Otitis Media and Ear Infection that is actively recruiting participants, run by AventaMed DAC. The registered enrollment target is 66 participants, below the 4,339-participant average among 14 other Otitis Media trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05741333, a NA study of Otitis Media and Ear Infection, is actively recruiting participants, sponsored by AventaMed DAC.
- RECRUITING
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
- 7
- Study locations
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the Solo+ Tympanostomy Tube Device (Solo+ TTD) for the placement of tympanostomy tubes in paediatric patients undergoing a tympanostomy procedure.
Primary Outcome
Percentage of subjects in which the Solo+ TTD tympanostomy tube is inserted in all indicated ears
Conditions Studied
Interventions
- DEVICE Solo+ Tympanostomy Tube Device (Solo+ TTD)
Study Locations (7)
Alabama
- Southern Head & Neck Surgery - Alexander City
- North Alabama ENT - Huntsville
- East Alabama ENT - Opelika
California
- Sacramento ENT - Sacramento
Kentucky
- Advanced ENT & Allergy - Louisville
Pennsylvania
- Specialty Physician Associates - Bethlehem
South Carolina
- South Carolina ENT - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-03-30 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT05741333 shows while recruiting
NCT05741333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 4,339-participant average among 14 other Otitis Media trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Otitis Media appearing as the primary indexed condition, and to 1 intervention - of which Solo+ Tympanostomy Tube Device (Solo+ TTD) is the first listed.
NCT05741333 lists 7 locations in 5 states (Alabama, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT05741333 about?
NCT05741333 is a clinical study titled "In-Office Clinical Study of the Solo+ TTD". The objective of this study is to evaluate the safety and effectiveness of the Solo+ Tympanostomy Tube Device (Solo+ TTD) for the placement of tympanostomy tubes in paediatric patients undergoing a tympanostomy procedure.
What is the current status of trial NCT05741333?
This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2023-03-30. Estimated completion is 2027-06.
What conditions does trial NCT05741333 study?
This clinical trial studies the following conditions: Otitis Media, Ear Infection.
What interventions are being tested in trial NCT05741333?
The interventions under investigation include: Solo+ Tympanostomy Tube Device (Solo+ TTD) (DEVICE).
Who is sponsoring clinical trial NCT05741333?
This trial is sponsored by AventaMed DAC, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05741333 being conducted?
This trial has 7 study locations across Alabama, California, Kentucky, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Otitis Media
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05741333's enrollment target sits among peer trials
66 12th of 14 higher than 3 of 14 other Otitis Media trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Otitis Media trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Coherent Optical Detection of Middle Ear Disease
RECRUITING · NA
-
Digital Otoscope Versus Education and Feedback for Otitis Media in Young Children
ACTIVE NOT RECRUITING · NA
-
The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population
COMPLETED · NA
-
In-Office Study of the Hummingbird® in Children 6 Months-21 Years Old
COMPLETED · NA
-
Middle Ear Disease Before Age 3, Treatment With Ear Tubes, and Literacy and Attentional Abilities at Ages 9 to 11
COMPLETED · NA
-
Tympanostomy Tube Placement in Children in the Office (Inova Study)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI